Design and synthesis of (4E)-4-(4-substitutedbenzylideneamino)-3-substituted-2,3-dihydro-2-thioxothiazole-5-carbonitrile as novel A2A receptor antagonists.
暂无分享,去创建一个
Nitin Kumar | Chandra Bhushan Mishra | Pratibha Mehta Luthra | Amresh Prakash | C. B. Mishra | Nitin Kumar | P. Luthra | Dimpy Sharma | Namrata Kumari | Amresh Prakash | N. Kumari | D. Sharma
[1] B. Fredholm,et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.
[2] L. Robertson,et al. Receptor interactions by polybrominated diphenyl ethers versus polychlorinated biphenyls: a theoretical Structure-activity assessment. , 2008, Environmental toxicology and pharmacology.
[3] A. Rolland,et al. Phenolic thiazoles as novel orally-active neuroprotective agents. , 2004, Bioorganic & medicinal chemistry letters.
[4] G. Cutter. Statistical issues in neutralizing antibodies , 2003, Neurology.
[5] D. Tulshian,et al. 6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists. , 2005, Bioorganic & medicinal chemistry letters.
[6] C. B. Mishra,et al. Synthesis of novel 7-imino-2-thioxo-3,7-dihydro-2H-thiazolo [4,5-d] pyrimidine derivatives as adenosine A2A receptor antagonists. , 2010, Bioorganic & medicinal chemistry letters.
[7] G. Spalluto,et al. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists. , 1996, Journal of medicinal chemistry.
[8] T. Shindou,et al. The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[9] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[10] G. Spalluto,et al. 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. , 2002, Journal of medicinal chemistry.
[11] P. Lestage,et al. In vivo neuroprotective effects of the novel imidazolyl nitrone free-radical scavenger (Z)-alpha-[2-thiazol-2-yl)imidazol-4-yl]-N-tert-butylnitrone (S34176). , 2005, European journal of pharmacology.
[12] E. Ongini,et al. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation , 2003, Neurology.
[13] C. B. Mishra,et al. Novel 8-(furan-2-yl)-3-benzyl thiazolo [5,4-e][1,2,4] triazolo [1,5-c] pyrimidine-2(3H)-thione as selective adenosine A2A receptor antagonist , 2011, Neuroscience Letters.
[14] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .
[15] C. B. Mishra,et al. Novel 8-(furan-2-yl)-3-substituted thiazolo [5,4-e][1,2,4] triazolo[1,5-c] pyrimidine-2(3H)-thione derivatives as potential adenosine A(2A) receptor antagonists. , 2010, Bioorganic & medicinal chemistry.
[16] J. Hubble,et al. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD , 2003, Neurology.
[17] A. Ludolph,et al. Protective Effects of Riluzole on Dopamine Neurons , 2000, Journal of neurochemistry.